This article explores the controversial topic of TAVR versus surgical AVR in low-risk patients. The primary outcome was 3-year survival. The authors report 3-year survival for TAVR and surgical AVR as 72% and 83.4%, respective (p=0.0015). Although TAVR is an exciting technology, there should be caution in adopting it in lower risk patients.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
TAVR (TAVI)
July 14, 2016
June 28, 2016
This article investigates the effects of varying degrees of aortic regurgitation (AR) on survival after transcatheter aortic valve replacement (TAVR). They retrospectively evaluated a cohort of 237 patients undergoing TAVR from 2006 to 2012 with echocardiogram performed within 30 days of the procedure. Using a Cox proportional multivariable regress
June 11, 2016
This manuscript reports on the 3-year follow up results of the CoreValve US Pivotal Trial in which patients with aortic stenosis at high risk for surgery were randomly assigned to self-expanding TAVR or SAVR in a 1:1 manner.
June 8, 2016
In medicine we often use words not understandable to patients. For example, instead of saying, "does it hurt when you pee,” we say, “dysuria”… Roughly 80% of patients don’t understand their medical condition (Am J Emerg Med. 2000; PMID 11103725). This cartoon animation provides a clear explanation to help patients understand aortic stenosis.
June 4, 2016
Neurologic outcomes were evaluated in a randomized trial of TAVR or surgical aortic valve replacement (SAVR) for severe AS (750 pts).
April 5, 2016
In this manuscript the authors report on their findings in a systematic review and meta-analysis of 18 studies looking into the effect on outcomes of balloon predilatation in patients undergoing transcatheter aortic valve implantation (TAVI).
April 3, 2016
Neil Moat, one of the busiest British surgeons involved directly and consistently in TAVR, discusses PARTNER 2 and SURTAVI, paying particular attention to the health economics of low-risk TAVR and the implication of reduced profile devices.
April 3, 2016
The PARTNER 2A trial randomized 2032 patients at intermediate operative risk (mean STS score of 6) to undergo either transcatheter or surgical aortic valve replacement. The primary endpoint of all-cause death or disabling stroke at 2 years was comparable for the two treatments: TAVR 19.3% versus SAVR 21.1%.
March 31, 2016
A panel of leading cardiac surgeons met at the 2016 SCTS Annual Meeting in Birmingham, United Kingdom, to discuss the current state of cardiac surgery, and what is on the horizon for the subspecialty.
March 28, 2016
A refreshing , adequately supported by pragmatic imaging, 22 minute presentation from an Arizona meeting that many surgeons would find quite informative and educating. Dr.